Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06346262

Seizure Rescue Medication (RM) as Part of a Comprehensive Epilepsy Self-management Package of Care

This study will be done in two phases. Using stakeholder input (community advisory board (CAB)), the study team will adapt the SMART program to incorporate education and self-management support for use of Rescue Medication (RM) to manage seizure occurrence among Persons With Epilepsy (PWE) who have repetitive seizures. Additional content/support materials, pending input stakeholder might include posters/hand-outs that present information on the use of RM in a way that is engaging and salient to PWE. It is expected that participants will be in Phase 1 for about 3 months and participate in the CAB 2 or 3 times via zoom for 60-90 minutes/meeting. The advisory board will provide input on needed refinement of an adapted version of SMART based on their individual experiences. It is anticipate the total time commitment to be no more than 6 hours over 3 months, spread out over 2-3 meetings with review of materials possible in between meetings.

Phase 2: The investigators will use a 6-month prospective trial design to test engagement with and effects of SMART-RM among approximately 35 adult (≥ 18 years) PWE who have repetitive seizures.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Epilepsy Brain Diseases Central Nervous System Diseases Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Seizures Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Phase 1 Patient with epilepsy inclusion criteria:

  • Have epilepsy
  • Have experience with RM
  • Be 18 years or older
  • Be able to speak and understand English
  • Be able to provide written, informed consent to study participation

Phase 1 Caregiver inclusion criteria

  • Provide care support to an individual with epilepsy
  • Be 18 years or older
  • Be able to speak and understand English
  • Be able to provide written, informed consent to study participation

Phase 1 Provider inclusion criteria

  • Provide care for individuals with epilepsy - this may include (not limited to) physician, nurse practitioner, physician assistant, nurse, social worker, psychologist
  • Be 18 years or older
  • Be able to speak and understand English
  • Be able to provide written, informed consent to study participation

Inclusion criteria

for PEs:

  • Have epilepsy
  • Have experience with RM
  • Be 18 years or older
  • Be able to speak and understand English
  • Be able to provide written, informed consent to study participation

Inclusion criteria

for participants who will receive SMART-RM:

  • Have received a previous diagnosis of epilepsy
  • Be adults ≥ age 18,
  • While on a regimen of anti-epileptic medication, still be experiencing bouts of seizures (e.g. frequent break through or acute repetitive seizures) distinct from their usual seizure pattern , and, in the opinion of the study epilepsy clinician, may need benzodiazepine intervention for seizure control
  • Have experienced at least 3 seizures but not more than 100 seizures in the previous 6 months. If there have only been 3 seizures in the last 6 months, two of the seizures should be within approximately 24 hours of each other (not more than 48 hours apart)
  • Be able to speak and understand English
  • Be able to provide written, informed consent to study participation

Exclusion criteria

Exclusion criteria

for participants who will receive SMART-RM:

  • Individuals who have had allergic reaction to diazepam or who have medical/psychiatric that are contraindications to the use of diazepam
  • Individuals prescribed opioid medications
  • Individuals with acute narrow angle glaucoma
  • Individuals with known dependence on benzodiazepines or current benzodiazepine abuse.
  • Actively suicidal/homicidal
  • Individuals with a diagnosis of dementia
  • Individuals who are unable to provide written informed consent to participate in study and who do not have a legally authorized representative or individuals who are unable to participate in study procedures.
  • Pregnant women

Treatment and study plan

SMART RM

Behavioral

The SMART-RM will consist of 8 group-format, 45-60 minute sessions (up to 11 participants per group), which will be collaboratively delivered by a Nurse Educator (NE) and a Peer Educator (PE).

Valtoco Nasal Product

Drug

Medication dosing will follow recommendations in the Valtoco package insert and managed by the epilepsy clinician.

Primary outcomes

  1. Change in number of seizures as measured by patient report.

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Change in quality of life as measure by QOLIE-31

    Time frame: Baseline, 10 week, 24 week

    Quality of life (QOL) will be assessed using the QOLIE-31, a validated tool to assess quality of life specifically in people with epilepsy with higher numbers reflecting a more favorable health state.

  2. Change in functional status as measure by Short-Form Health Survey (SF-36)

    Time frame: Baseline, 10 week, 24 week

    Functional status will be assessed using the 36-item Short-Form Health Survey (SF-36), a multipurpose, short-form health survey with 36 questions that yields two psychometrically based components: a physical component summary and mental component summary. Scores range from 0 (worst functioning) to 100 (best functioning). The SF-36 is a generic measure of functional health status and has proven useful for comparing the relative burden of diseases.

  3. Change in depressive symptoms as measure by Patient Health Questionnaire (PHQ-9)

    Time frame: Baseline, 10 week, 24 week

    Depressive symptom severity will be assessed using the nine- item Patient Health Questionnaire (PHQ-9), a widely used and validated self-rated depression scale. The PHQ-9 incorporates Diagnostic and Statistical Manual of Mental Disorders diagnostic criteria, with scores ranging from 0 to 27. Higher scores indicate worse depression severity. The PHQ-9 has been widely used to measure depressive symptom severity in epilepsy.

  4. Change in epilepsy self management as measure by Epilepsy Self-Efficacy Scale (ESES)

    Time frame: Baseline, 10 week, 24 week

    Self-efficacy will be measured using the 33-item Epilepsy Self-Efficacy Scale (ESES), with scores ranging from 0 to 330 and higher scores indicating better self-efficacy. Social support will be measured with the 12-item.

  5. Change in epilepsy self management as measure by Multidimensional Scale of Perceived Social Support (MSPSS)

    Time frame: Baseline, 10 week, 24 week

    Multidimensional Scale of Perceived Social Support (MSPSS), which measures perception of social support provided by family and friends, as well as satisfaction with that support. The MSPSS score ranges from 1 to 84, with higher scores indicating better social support.

  6. Change in epilepsy self management as measure by Epilepsy Self-Management Scale (ESMS)

    Time frame: Baseline, 10 week, 24 week

    Overall epilepsy self-management competency will be measured using the Epilepsy Self-Management Scale (ESMS); scores range from 1 to 190, with higher scores indicating better self-management of epilepsy.

  7. Change in epilepsy self management as measure by Epilepsy Stigma Scale (ESS)

    Time frame: Baseline, 10 week, 24 week

    Stigma for epilepsy will be measured using the Epilepsy Stigma Scale (ESS) In the ESS, scores range from 7 to 70; each item is rated on a 7-point scale from strongly disagree to strongly agree, with higher numbers indicating greater perceived stigma

  8. Change in number of emergency room visit as measure by patient report

    Time frame: Baseline, 10 week, 24 week

  9. Change in number of hospitalizations as measure by patient report

    Time frame: Baseline, 10 week, 24 week

  10. Change in number of non study outpatient services utilization as measure by patient report

    Time frame: Baseline, 10 week, 24 week

Sponsors and collaborators

Lead sponsor

University Hospitals Cleveland Medical Center

Other

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Apr 4, 2024
Registry last updated
Jul 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.